BridgeBio is pointing to the approved indication for Attruby as it gears up to launch the drug with a list price of $18,759 for a 28-day supply, saying it is the only drug with a label that says ...
The drug, known scientifically as acoramidis, will be sold by BridgeBio under the brand name Attruby. The FDA cleared Attruby to treat patients with the heart condition known as transthyretin ...
The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...
6don MSNOpinion
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...
Mizuho Securities analyst Salim Syed has assigned their bullish stance on BBIO stock, giving a Buy rating on November 25.Don't Miss our Black ...
BridgeBio’s Attruby may be even more effective. The twice a day pill regimen reduced the risk of death and recurrent cardiovascular hospitalizations by 42% after 30 months of treatment.
Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback